Pharma Industry On How To Tackle EU Regulatory & Reimbursement Barriers To Digital Therapeutics
Executive Summary
When it comes to digital therapeutics in Europe, EFPIA says there is a lack of harmonization in the regulatory requirements, and only Belgium and Germany offer value assessment, reimbursement and funding pathways, with more intermittent offerings in countries like France and the UK.